title: Percutaneous tumor ablation for hepatocellular carcinoma.
abstract: OBJECTIVE
  This report reviews the current clinical status of percutaneous ablation of hepatocellular carcinoma (HCC).
  
  
  CONCLUSIONS
  HCC is increasing in incidence. Multiple percutaneous ablation methods are now available for primary treatment or for bridging to transplantation. Percutaneous ethanol instillation and radiofrequency ablation are the most extensively evaluated percutaneous treatments for HCC. Newer technologies are being evaluated and may change future practice patterns.
authors.affiliation: Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, White 270, 55 Fruit St, Boston, MA 02214, USA. dgervais@partners.org
authors.forename: Debra A
authors.initials: DA
authors.lastname: Gervais
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Arellano
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D016461:Chemoembolization, Therapeutic / Q000379:methods; D017679:Cryotherapy / Q000379:methods; D018274:Electroporation / Q000379:methods; D000431:Ethanol / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery*; D008872:Microwaves / Q000627:therapeutic use
chemical_list: D000431:Ethanol